• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

匹配肽段:为生物制药应用优化匹配分子对分析

Matched Peptides: Tuning Matched Molecular Pair Analysis for Biopharmaceutical Applications.

作者信息

Fuchs Julian E, Wellenzohn Bernd, Weskamp Nils, Liedl Klaus R

机构信息

Theoretical Chemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck , Innrain 82, 6020 Innsbruck, Austria.

Research Germany/Lead Identification and Optimization Support, Boehringer Ingelheim Pharma GmbH & Co. KG , Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany.

出版信息

J Chem Inf Model. 2015 Nov 23;55(11):2315-23. doi: 10.1021/acs.jcim.5b00476. Epub 2015 Nov 6.

DOI:10.1021/acs.jcim.5b00476
PMID:26501781
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4658635/
Abstract

Biopharmaceuticals hold great promise for the future of drug discovery. Nevertheless, rational drug design strategies are mainly focused on the discovery of small synthetic molecules. Herein we present matched peptides, an innovative analysis technique for biological data related to peptide and protein sequences. It represents an extension of matched molecular pair analysis toward macromolecular sequence data and allows quantitative predictions of the effect of single amino acid substitutions on the basis of statistical data on known transformations. We demonstrate the application of matched peptides to a data set of major histocompatibility complex class II peptide ligands and discuss the trends captured with respect to classical quantitative structure-activity relationship approaches as well as structural aspects of the investigated protein-peptide interface. We expect our novel readily interpretable tool at the interface of cheminformatics and bioinformatics to support the rational design of biopharmaceuticals and give directions for further development of the presented methodology.

摘要

生物制药对药物研发的未来有着巨大的前景。然而,合理的药物设计策略主要集中在发现小型合成分子上。在此,我们介绍匹配肽,这是一种用于与肽和蛋白质序列相关的生物数据的创新分析技术。它代表了匹配分子对分析向大分子序列数据的扩展,并允许基于已知转化的统计数据对单个氨基酸取代的影响进行定量预测。我们展示了匹配肽在主要组织相容性复合体II类肽配体数据集上的应用,并讨论了相对于经典定量构效关系方法所捕捉到的趋势以及所研究的蛋白质 - 肽界面的结构方面。我们期望我们在化学信息学和生物信息学界面的新型易于解释的工具能够支持生物制药的合理设计,并为所提出方法的进一步发展指明方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5727/4658635/b20e3179d69f/ci-2015-004768_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5727/4658635/076f08ce6908/ci-2015-004768_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5727/4658635/9964aaba311d/ci-2015-004768_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5727/4658635/cf631b52bea8/ci-2015-004768_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5727/4658635/b20e3179d69f/ci-2015-004768_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5727/4658635/076f08ce6908/ci-2015-004768_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5727/4658635/9964aaba311d/ci-2015-004768_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5727/4658635/cf631b52bea8/ci-2015-004768_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5727/4658635/b20e3179d69f/ci-2015-004768_0004.jpg

相似文献

1
Matched Peptides: Tuning Matched Molecular Pair Analysis for Biopharmaceutical Applications.匹配肽段:为生物制药应用优化匹配分子对分析
J Chem Inf Model. 2015 Nov 23;55(11):2315-23. doi: 10.1021/acs.jcim.5b00476. Epub 2015 Nov 6.
2
A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.一种重组单链人II类主要组织相容性复合体分子(HLA-DR1),作为α链、β链和抗原肽的共价连接异源三聚体,在体外具有免疫原性,且对细菌超抗原的亲和力降低。
Eur J Immunol. 1997 Aug;27(8):1933-41. doi: 10.1002/eji.1830270817.
3
Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.与HLA - DR1结合的主要天然加工肽源自MHC相关分子,且大小各异。
Nature. 1992 Aug 27;358(6389):764-8. doi: 10.1038/358764a0.
4
An iterative approach to class II predictions.用于II类预测的迭代方法。
Methods Mol Biol. 2007;409:341-53. doi: 10.1007/978-1-60327-118-9_25.
5
A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding.肽结合诱导的人类主要组织相容性复合体蛋白HLA-DR1的构象变化。
Biochemistry. 1999 May 4;38(18):5878-87. doi: 10.1021/bi983048m.
6
Accuracy of a structural homology model for a class II histocompatibility protein, HLA-DR1: comparison to the crystal structure.II类组织相容性蛋白HLA-DR1的结构同源性模型的准确性:与晶体结构的比较
J Biomol Struct Dyn. 1995 Jun;12(6):1213-33. doi: 10.1080/07391102.1995.10508808.
7
Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex.肽与 MHCII 的α亚单位连接,形成稳定的反向抗原呈递复合物。
J Mol Biol. 2012 Oct 26;423(3):294-302. doi: 10.1016/j.jmb.2012.07.008. Epub 2012 Jul 20.
8
Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.关于恒定链肽在人白细胞抗原-DR1上释放或交换抗原肽活性的研究。
Arzneimittelforschung. 1999 Sep;49(9):791-9.
9
A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins.II类主要组织相容性复合体(MHC)蛋白中P10位置的多态性口袋有助于肽结合特异性。
Chem Biol. 2004 Oct;11(10):1395-402. doi: 10.1016/j.chembiol.2004.08.007.
10
Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides.在体外和体内均未能证明存在长期的MHC饱和现象。对MHC阻断肽治疗潜力的影响。
J Immunol. 1994 May 1;152(9):4310-9.

引用本文的文献

1
In Silico and In Vitro Potential Antifungal Insights of Insect-Derived Peptides in the Management of sp. Infections.昆虫衍生肽在管理sp.感染中的计算机模拟和体外潜在抗真菌见解
Int J Mol Sci. 2025 Aug 1;26(15):7449. doi: 10.3390/ijms26157449.
2
PepFuNN: Novo Nordisk Open-Source Toolkit to Enable Peptide in Silico Analysis.PepFuNN:诺和诺德公司用于实现肽段计算机模拟分析的开源工具包。
J Pept Sci. 2025 Feb;31(2):e3666. doi: 10.1002/psc.3666.
3
Automatic Identification of Analogue Series from Large Compound Data Sets: Methods and Applications.

本文引用的文献

1
Novel delivery systems for improving the clinical use of peptides.新型递药系统改善肽类药物的临床应用
Pharmacol Rev. 2015 Jul;67(3):541-61. doi: 10.1124/pr.113.008367.
2
Patent watch: Have the biosimilar floodgates been opened in the United States?专利观察:美国的生物类似药闸门是否已经打开?
Nat Rev Drug Discov. 2015 May;14(5):303-4. doi: 10.1038/nrd4622.
3
Strong nonadditivity as a key structure-activity relationship feature: distinguishing structural changes from assay artifacts.强非加和性作为关键的构效关系特征:区分结构变化与检测假象。
自动识别大型化合物数据集的类似物系列:方法与应用。
Molecules. 2021 Aug 31;26(17):5291. doi: 10.3390/molecules26175291.
4
Matched Molecular Pair Analysis in Short: Algorithms, Applications and Limitations.简而言之:匹配分子对分析——算法、应用与局限
Comput Struct Biotechnol J. 2016 Dec 13;15:86-90. doi: 10.1016/j.csbj.2016.12.003. eCollection 2017.
5
Computer-aided drug design at Boehringer Ingelheim.勃林格殷格翰的计算机辅助药物设计
J Comput Aided Mol Des. 2017 Mar;31(3):275-285. doi: 10.1007/s10822-016-9975-3. Epub 2016 Sep 20.
J Chem Inf Model. 2015 Mar 23;55(3):483-94. doi: 10.1021/acs.jcim.5b00018. Epub 2015 Mar 11.
4
Understanding our love affair with p-chlorophenyl: present day implications from historical biases of reagent selection.理解我们对氯苯的钟情:试剂选择历史偏见对当今的影响。
J Med Chem. 2015 Mar 12;58(5):2390-405. doi: 10.1021/jm501894t. Epub 2015 Feb 19.
5
Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.监管观察:生物新分子实体的创新:1986 - 2014年
Nat Rev Drug Discov. 2015 Feb;14(2):83. doi: 10.1038/nrd4535.
6
2014 FDA drug approvals.2014年美国食品药品监督管理局批准的药物
Nat Rev Drug Discov. 2015 Feb;14(2):77-81. doi: 10.1038/nrd4545.
7
Quantitative prediction of class I MHC/epitope binding affinity using QSAR modeling derived from amino acid structural information.利用源自氨基酸结构信息的定量构效关系模型对I类主要组织相容性复合体/表位结合亲和力进行定量预测。
Comb Chem High Throughput Screen. 2015;18(1):75-82. doi: 10.2174/1386207318666150121125746.
8
Structural Insights Into HLA-DM Mediated MHC II Peptide Exchange.HLA-DM介导的MHC II肽交换的结构见解
Curr Top Biochem Res. 2011;13(2):39-55.
9
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.克服生物制药给药方面的挑战:制剂与递送策略。
Nat Rev Drug Discov. 2014 Sep;13(9):655-72. doi: 10.1038/nrd4363. Epub 2014 Aug 8.
10
Large scale characterization of the LC13 TCR and HLA-B8 structural landscape in reaction to 172 altered peptide ligands: a molecular dynamics simulation study.针对172种改变的肽配体反应中LC13 TCR和HLA - B8结构格局的大规模表征:一项分子动力学模拟研究。
PLoS Comput Biol. 2014 Aug 7;10(8):e1003748. doi: 10.1371/journal.pcbi.1003748. eCollection 2014 Aug.